




In the Claims:



54. (New) A compound according to the formula:



Wherein B is

or


;

R is H, F, Cl, Br, I, C₁-C₄ alkyl, -C≡N, -C≡C-R_a,  or  ;


X is H, C₁-C₄ alkyl, F, Cl, Br or I;

R¹ is H, an acyl group, a C₁-C₂₀ alkyl or an ether group;

R² is H, an acyl group, a C₁-C₂₀ alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a





or






group;


Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;

R⁸ is H or a C₁-C₂₀ alkyl or ether group;

R³ is a C₁, C₃ or C₄ alkyl group, $-(CH_2)_n-C\equiv C-R_a$,  or 

when B is  and

R³ is C₁-C₄ alkyl, $-(CH_2)_n-C\equiv C-R_a$,  or  when B is



R^{3a} and R^{3b} are each independently H, F, Cl, Br and I;


R_a is H, F, Cl, Br, I, or -C₁-C₄ alkyl;

Y is H, F, Cl, Br, I or -C₁-C₄ alkyl; and

k is 0, 1 or 2;


n is 0, 1, 2, 3, 4 or 5;

or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof.




55. (New) The compound according to claim 54 wherein B is

56. (New) The compound according to claim 55 wherein R^3 is $-(CH_2)_n-C\equiv C-R_a$,



57. (New) The compound according to claim 56 wherein R is F, Cl, Br, I, C_1-C_3 alkyl,




58. (New) The compound according to claim 56 wherein R is CH_3 , R^3 is $-(CH_2)_n-C\equiv C-R_a$, n is 0 and R_a is H.

59. (New) The compound according to claim 58 wherein R^{3a} and R^{3b} are both H.


60. (New) The compound according to claim 58 wherein R^2 is H.

61. (New) The compound according to claim 54 which is




62. (New) The compound according to claim 61 wherein R^2 is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.

63. (New) The compound according to claim 61 wherein R^2 is H.




64. (New) The compound according to claim 54 wherein B is

65. (New) The compound according to claim 64 wherein R^3 is CH_3 , $-(\text{CH}_2)_n-\text{C}\equiv\text{C}-\text{R}_a$,



66. (New) The compound according to claim 65 wherein R is H, F, Cl, Br, I, CH_3 ,






67. (New) The compound according to claim 64 wherein R is CH_3 , R^3 is $-(\text{CH}_2)_n-\text{C}\equiv\text{C}-\text{R}_a$, n is 0 and R_a is H.

68. (New) The compound according to claim 67 wherein R^{3a} and R^{3b} are both H.

69. (New) The compound according to claim 68 wherein R^2 is H.

70. (New) A pharmaceutical composition comprising an effective amount of a compound for use in the treatment of a viral disease state, disorder or a condition associated with a viral disease state according to the formula:




Wherein B is

or

;


R is H, F, Cl, Br, I, C₁-C₄ alkyl, -C≡N, -C≡C-R_a,




X is H, C₁-C₄ alkyl, F, Cl, Br or I;

R¹ is H, an acyl group, a C₁-C₂₀ alkyl or an ether group;

R² is H, an acyl group, a C₁-C₂₀ alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a





or






group;


Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;

R⁸ is H or a C₁-C₂₀ alkyl or ether group;

R³ is a C₁, C₃ or C₄ alkyl group, $-(CH_2)_n-C\equiv C-R_a$,  or 

when B is  and

R³ is C₁-C₄ alkyl, $-(CH_2)_n-C\equiv C-R_a$,  or  when B is



R^{3a} and R^{3b} are each independently H, F, Cl, Br and I;


R_a is H, F, Cl, Br, I, or -C₁-C₄ alkyl;

Y is H, F, Cl, Br, I or -C₁-C₄ alkyl;

k is 0, 1 or 2; and


n is 0, 1, 2, 3, 4 or 5;

or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof in combination with a pharmaceutically acceptable carrier, additive or excipient.




71. (New) The composition according to claim 70 wherein B is

72. (New) The composition according to claim 71 wherein R^3 is $-(CH_2)_n-C\equiv C-R_a$,



73. (New) The composition according to claim 72 wherein R is F, Cl, Br, I, C_1-C_3 alkyl,




74. (New) The composition according to claim 71 wherein R is CH_3 , R^3 is $-(CH_2)_n-C\equiv C-R_a$, n is 0 and R_a is H.

75. (New) The composition according to claim 74 wherein R^{3a} and R^{3b} are both H.


76. (New) The composition according to claim 75 wherein R^2 is H.

77. (New) The composition according to claim 70 wherein said compound is




78. (New) The composition according to claim 77 wherein R^2 is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.

79. (New) The composition according to claim 77 wherein R^2 is H.




80. (New) The composition according to claim 70 wherein B is

81. (New) The composition according to claim 80 wherein R^3 is CH_3 , $-(\text{CH}_2)_n-\text{C}\equiv\text{C}-\text{R}_a$,



82. (New) The composition according to claim 81 wherein R is H, F, Cl, Br, I, CH_3 ,




83. (New) The composition according to claim 80 wherein R is CH_3 , R^3 is $-(\text{CH}_2)_n-\text{C}\equiv\text{C}-\text{R}_a$, n is 0 and R_a is H.

84. (New) The composition according to claim 83 wherein R^{3a} and R^{3b} are both H.

85. (New) The composition according to claim 84 wherein R^2 is H.

86. (New) The composition according to claim 70 wherein said compound is



Where R^1 is H or an acyl group; and

R^2 is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.

87. (New) The composition according to claim 86 wherein R^1 is H and R^2 is H.